UnitedHealth (UNH) reported strong Q3 results, while its ongoing initiatives to address prior authorizations, improve pharmacy transparency and affordability, and strengthen governance are encouraging, Truist Securities said Tuesday in a note.

The company reported Q3 adjusted EPS of $4.69 on revenue of $112.7 billion, beating Truist estimates of $4.01 and $110.7 billion, respectively. UnitedHealth also raised its 2026 adjusted EPS guidance to at least $20.50, up from its prior range of $19.50 to $20, according to the note.

UnitedHealth highlighted 2027 Star ratings that were in line with management's expectations, with at least 69% of members enrolled in 4 Star plans or higher. The company also reported improvement in 11 of 12 HEDIS measures and all four pharmacy measures, the note added.

Truist kept a buy rating on UnitedHealth with a $500 price target.

Price: 378.84, Change: +0.31, Percent Change: +0.08